A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
Phase of Trial: Phase I/II
Latest Information Update: 08 Feb 2019
At a glance
- Drugs Atezolizumab (Primary) ; Isatuximab (Primary)
- Indications Glioblastoma; Head and neck cancer; Liver cancer; Ovarian cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 23 Aug 2018 Planned End Date changed from 16 Nov 2021 to 14 Sep 2022.
- 23 Aug 2018 Planned primary completion date changed from 16 Nov 2021 to 14 Sep 2022.
- 08 Aug 2018 New trial record